North Bay Neuroscience Institute

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2018

Legal Domicile

Principal Officer

Maben Rainwater

Phone

7078273593

Tax Period

2019-01-01 to 2019-12-31

North Bay Neuroscience Institute, founded in 2018, is a small nonprofit that reported $881K in total revenue in fiscal year 2019. Revenue surged 180% from the prior year, signaling strong growth momentum. The organization ran a surplus of $195K, a strong 22% operating margin.

Mission

Our work involves researching different potential medicines that may impact the onset of Alzheimers Disease. We work with pharmaceutical companies which are in various trial stages of developing these new drugs. Our job is to work with patients subjects who have early Alzheimer indications and want to try these trial drugs. Their participation in these studies helps us all understand ways to beat Alzheimers Disease.

Program Service Accomplishments

Program 1

Expenses: $124,790 Revenue: $445,233

Novartis: Generation 1 & 2 - Tests the safety and effects of the investgational drug CNP520 in cognitively normal older adults who are at risk of developing dementia based on their age, genetic...

Novartis: Generation 1 & 2 - Tests the safety and effects of the investgational drug CNP520 in cognitively normal older adults who are at risk of developing dementia based on their age, genetic status, and brain amyloid levels.

Program 2

Expenses: $23,634 Revenue: $272,189

Biogen: Emerge Study - Evaluates the efficacy of the experimental drug aducanumab compared with a placebo in slowing cognitive and functional impairment in people with early-stage Alzheimer's disease.

Program 3

Expenses: $22,119 Revenue: $80,858

Roche: Cread - This clinical trial tests the experimental drug crenezumab in people with early to mild Alzheimer's disease. It assesses the drug's safety and efficacy and evaluates any changes in...

Roche: Cread - This clinical trial tests the experimental drug crenezumab in people with early to mild Alzheimer's disease. It assesses the drug's safety and efficacy and evaluates any changes in particiapants' dementia rating and performanmce on neuropsychological tests.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2019)

Revenue Breakdown

Contributions & Grants $2,100

Program Service Revenue $878,970

Investment Income $0

Other Revenue $0

TOTAL REVENUE $881,070

Expense Breakdown

Grants Paid $0

Salaries & Benefits $409,659

Fundraising Expenses $0

Program Expenses $189,442

Other Expenses $276,396

TOTAL EXPENSES $686,055

Year-over-Year Comparison

	2019	2018	Change
Revenue	$881,070	$314,174	+1.8%
Expenses	$686,055	$256,460	+1.7%
Net Income	$195,015	$57,714	+2.4%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$225,856

Total Directors

$90,774

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
Terry Hess	Foundation Mgr.	40.00	Officer	$135,082	$0	$135,082
Maben Rainwater	Executive Dir.	40.00	Officer Director	$90,774	$0	$90,774
Beth Bollinger	Chairman	1.00	Director	$0	$0	$0
Soraya Saffarinia	Secretary	0.00	Officer Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2019	$881,070	$686,055	$265,276	$195,015